Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study.
Ficorella C, Morelli MF, Ricevuto E, Cannita K, Porzio G, Baldi PL, Cianci G, DI Rocco ZC, Natoli C, Tinari N, DE Galitiis F, Calista F, Marchetti P. Ficorella C, et al. Among authors: de galitiis f. Br J Cancer. 2004 Aug 16;91(4):618-20. doi: 10.1038/sj.bjc.6601971. Br J Cancer. 2004. PMID: 15292944 Free PMC article. Clinical Trial.
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Luke JJ, et al. Among authors: de galitiis f. J Clin Oncol. 2024 May 10;42(14):1619-1624. doi: 10.1200/JCO.23.02355. Epub 2024 Mar 7. J Clin Oncol. 2024. PMID: 38452313 Free PMC article. Clinical Trial.
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Ascierto PA, Di Giacomo AM, Chiarion Sileni V, Queirolo P, Spagnolo F, De Galitiis F, Cognetti F, Mandalà M, Guidoboni M, Rinaldi G, Depenni R, Consoli F, Troiani T, Guida M, Marconcini R, Ferrucci PF, Strippoli S, Fava P, Merelli B, Simeone E, Di Guardo L, Giannarelli D, Maio M, Quaglino P, Del Vecchio M. Ascierto PA, et al. Among authors: de galitiis f. Eur J Cancer. 2023 Sep;191:113246. doi: 10.1016/j.ejca.2023.113246. Epub 2023 Jul 19. Eur J Cancer. 2023. PMID: 37549531
[The adjuvant therapy of colonic carcinoma in old age].
Ficorella C, Cannita K, Ricevuto E, Porzio G, Trapasso T, De Galitiis F, Gallà DA, Morese R, D'Addario M, Marchetti P. Ficorella C, et al. Among authors: de galitiis f. Minerva Med. 1999 Jul-Aug;90(7-8):232-3. Minerva Med. 1999. PMID: 10719426 Italian. No abstract available.
[Familiarity and heredity of tumors in function of an early surgical therapeutic approach].
Ricevuto E, Di Rocco ZC, Cianci G, Bisegna R, Casilli F, De Galitiis F, Cannita K, Calista F, Porzio G, Bafile A, Vicentini R, Resta V, De Rubeis G, Martinotti S, Ficorella C, Marchetti P. Ricevuto E, et al. Among authors: de galitiis f, de rubeis g. Suppl Tumori. 2002 May-Jun;1(3):S89-91. Suppl Tumori. 2002. PMID: 12415797 Review. Italian. No abstract available.
Prognostic value of p53 molecular status in high-risk primary breast cancer.
Marchetti P, Cannita K, Ricevuto E, De Galitiis F, Di Rocco ZC, Tessitore A, Bisegna R, Porzio G, De Rubeis GP, Ventura T, Martinotti S, Ficorella C. Marchetti P, et al. Among authors: de rubeis gp, de galitiis f. Ann Oncol. 2003 May;14(5):704-8. doi: 10.1093/annonc/mdg197. Ann Oncol. 2003. PMID: 12702523 Free article.
[Can analysis of the molecular status of the p53 gene contribute to improving the therapeutic strategy for breast carcinoma?].
Ricevuto E, Marchetti P, Cannita K, De Galitiis F, Di Rocco ZC, Tessitore A, Martella F, Bisegna R, Porzio G, Bafile A, Vicentini R, Resta V, Mattucci S, Ventura T, Martinotti S, de Rubeis GP, Ficorella C. Ricevuto E, et al. Among authors: de rubeis gp, de galitiis f. Tumori. 2003 Jul-Aug;89(4 Suppl):197-9. Tumori. 2003. PMID: 12903592 Review. Italian.
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Ficorella C, Ricevuto E, Morelli MF, Morese R, Cannita K, Cianci G, Porzio G, Di Rocco ZC, De Galitiis F, De Tursi M, Tinari N, Iacobelli S, Marchetti P. Ficorella C, et al. Among authors: de galitiis f, de tursi m. Oncol Rep. 2006 May;15(5):1345-50. doi: 10.3892/or.15.5.1345. Oncol Rep. 2006. PMID: 16596209 Clinical Trial.
Novel P53 mutations detected by FAMA in colorectal cancers.
De Galitiis F, Cannita K, Tessitore A, Martella F, Di Rocco ZC, Russo A, Adamo V, Iacobelli S, Martinotti S, Marchetti P, Ficorella C, Ricevuto E; Consorzio Interuniversitario Nazionale Bio-Oncologia. De Galitiis F, et al. Ann Oncol. 2006 Jun;17 Suppl 7:vii78-83. doi: 10.1093/annonc/mdl957. Ann Oncol. 2006. PMID: 16760300 Free article.
50 results